FDA OKS NEW GENERIC HIV DRUG FOR OVERSEAS MARKETING

JULY 01, 2006

The FDA has granted tentative approval for generic abacavir sulfate tablets—the first generic version of Glaxo- SmithKline's Ziagen anti-HIV medication. The generic product will be manufactured by Aurobindo Pharma Ltd of Hyderabad, India, and will be available for consideration for purchase under the President's Emergency Plan for AIDS Relief.

The FDA's tentative approval of this product means that Aurobindo's product meets all of the FDA's manufacturing quality and clinical safety and efficacy standards. Although existing patents preclude marketing the new generic in the United States, the drug can be sold abroad and used under the President's plan.




SHARE THIS SHARE THIS
0

Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.